表紙
市場調查報告書
商品編碼
1025093

全球藥物發現和早期開發外包市場:增長機會分析

Global Drug Discovery and Early Development Outsourcing Growth Opportunities

出版日期: | 出版商: Frost & Sullivan | 英文 58 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2020 年全球藥物發現和早期開發外包市場將達到 196.5 億美元,預計在預測期內以 6.4% 的複合年增長率增長。按地區劃分,北美繼續引領市場。

本報告調查了全球藥物發現和早期開發外包市場、市場概況/市場背景、市場增長促進劑/抑製劑分析、按臨床階段、服務類型劃分的藥物開發管道。總結了其他收入規模的趨勢和預測,主要 CRO 和 CDMO 的未來展望、競爭環境以及增長機會分析。

目錄

戰略要求

  • 為什麼增長變得更加困難
  • 戰略要務 8
  • 三大戰略建議的市場影響
  • 促進增長管道引擎的增長機會

市場概況/市場動態/研發情況

  • 醫藥市場
  • 醫藥市場:前 20 名製藥公司
  • 醫藥市場:研發成本
  • 製藥企業研發成本前20名
  • 全球臨床開發支出前景:按治療部門
  • 藥物開發管道:按臨床階段:世界
  • 藥物開發管道:按臨床階段:北美
  • 藥物開發管道:按臨床階段:歐洲
  • 風險投資情況:按臨床階段
  • 併購情況

增長機會分析

  • 分析範圍
  • 主要增長指標
  • 主要公司
  • 主要服務
  • 增長因素
  • 生長抑製劑
  • 按市場分類/服務類型
  • 收入預測
  • 收入預測:按服務類型
  • 主要驅動因素:按地區
  • 主要趨勢:按治療
  • 趨勢分析:按服務
  • 競爭環境
  • 主要進入者的能力概況
  • 主要 CRO 的未來展望
  • 主要 CDMO 的未來展望
  • 藥物發現的演化和初始開發價值鏈

增長機會領域

  • 增長機會:早期藥物發現中的 AI(先導選擇/優化)
  • 增長機會:針對 RNA 靶向小分子療法的高通量篩選
  • 增長機會:亞太地區的體外/體內藥理服務
  • 增長機會:新一代生物製藥的新表達平台

下一步

目錄
Product Code: PBEB-52

Growing Research and Development Pipelines of Emerging Biopharmaceutical and Niche Technology Providers Drive Competitive Intensity

Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions. The report identifies the evolving competitive landscape and initiatives taken by key contract research organizations (CRO) and contract development and manufacturing organizations (CDMO) to adapt to the growing needs of pharmaceutical and biotechnology sponsors.

The drug discovery and early development outsourcing market was worth $19.65 billion in 2020 and is estimated to grow at a compound annual growth rate of 6.4% up to 2026, with North America continuing to lead the market. In terms of overall R&D expenditure, the contribution of large pharmaceutical companies is steadily declining due to their focus on leaner portfolios. In contrast, the contribution of emerging biotechnology companies to drug development has grown more than 80% since 2018. Pharmaceutical companies are directing their R&D spending mainly toward strengthening their oncology portfolio and increasing year-on-year acquisitions of clinical-stage biopharmaceutical companies focusing on oncology therapy, suggesting both the potential of new technologies and promising returns on investment for these assets. Leading CROs and CDMOs are also focused on oncology, with anticancer drugs reportedly contributing the highest to the drug development pipeline in 2020. COVID-19-related drug discovery and early development research is projected to slow down in 2022 as most projects would have advanced to the clinical research stage by then. When pandemic-related restrictions are lifted, a surge in outsourcing for the next two years is expected as companies resume their non-COVID-19 drug discovery programs that were stalled during the pandemic.

In the United States and Europe, testing service providers with best-in-class good laboratory practices (GLP) and good track records are the preferred partner for completing investigational new drugs-enabling studies. Global CROs may have in-house capabilities, but pharmaceutical companies still prefer independent validation from specialists to minimize the risk of failure early on in the development life cycle before moving toward regulatory filing. Key industry participants are positioning themselves to be end-to-end integrated service providers for pharmaceutical and biotechnology sponsors. The growing demand for end-to-end integrated drug discovery and development support is closing the gap that distinguishes a CRO from a CDMO. The promise of artificial intelligence in drug discovery, along with novel approaches to target "undruggable" RNA, is set to drive small molecule drug discovery and outsourcing while the growth in biologics is expected to boost the need for better disease models and advanced in vivo pharmacology capabilities. Exploring novel expression systems to support the urgent needs of infectious disease management is also forecast to gain momentum especially as the industry favors single-use reactors for future biotherapeutics.

Table of Contents

Strategic Imperatives

  • Why Is It Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top Three Strategic Imperatives on the Global Drug Discovery and Early Development Outsourcing Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Market Overview and Dynamics-R&D Landscape

  • Pharmaceutical Market
  • Pharmaceutical Market-Top 20 Pharma Companies
  • Pharmaceutical Market-Global R&D Expenditure
  • Top 20 Pharma Companies' R&D Expenditure
  • Global Clinical Development Expenditure by Therapy Area
  • Global Drug Development Pipeline by Clinical Phase
  • Drug Development Pipeline by Clinical Phase-North America
  • Drug Development Pipeline by Clinical Phase-Europe
  • Venture Capital Landscape by Clinical Phase
  • M&A Landscape
  • M&A Landscape (continued)
  • M&A Landscape (continued)

Growth Opportunity Analysis

  • Scope of Analysis
  • Key Growth Metrics
  • Key Competitors
  • Key Services
  • Growth Drivers for the Drug Discovery and Early Development Outsourcing Market
  • Growth Restraints for the Drug Discovery and Early Development Outsourcing Market
  • Market Segmentation by Service Type
  • Revenue Forecast
  • Revenue Forecast by Service Type
  • Revenue Forecast Analysis
  • Revenue Forecast Analysis (continued)
  • Key Drivers by Region
  • Key Trends Analysis by Therapy
  • Key Trends Analysis by Service
  • Competitive Environment
  • Competitive Landscape
  • Key Participants' Capability Profile
  • Future Outlook for Key CROs
  • Future Outlook for Key CDMOs
  • Evolution of Drug Discovery and Early Development Value Chain

Growth Opportunity Universe

  • Growth Opportunity 1-AI in Early Drug Discovery (Lead Selection and Optimization)
  • Growth Opportunity 1-AI in Early Drug Discovery (Lead Selection and Optimization) (continued)
  • Growth Opportunity 2-High-throughput Screening for RNA-targeting Small Molecule Therapy
  • Growth Opportunity 2-High-throughput Screening for RNA-targeting Small Molecule Therapy (continued)
  • Growth Opportunity 3-Ex vivo/In vivo Pharmacology Services in APAC
  • Growth Opportunity 3-Ex vivo/In vivo Pharmacology Services in APAC (continued)
  • Growth Opportunity 4-Emerging Expression Platforms for Next-generation Biologics
  • Growth Opportunity 4-Emerging Expression Platforms for Next-generation Biologics (continued)

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • List of Exhibits (continued)
  • Legal Disclaimer